Thursday, September 5, 2013

GSK cancer vaccine misses target in melanoma trial

LONDON (Reuters) - An experimental cancer vaccine from GlaxoSmithKline failed to meet the first of two joint targets in a closely watched late-stage clinical trial, dealing a blow to the high-risk, high-reward project.






No comments:

Post a Comment

Subscribe Now: Feed Icon